Aspergillosis Treatment Market Report 2026

The aspergillosis treatment market size has grown strongly in recent years. It will grow from $3.3 billion in 2025 to $3.49 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing incidence of immunocompromised patient populations, rising hospital-acquired fungal infections, availability of conventional antifungal drugs, improved clinical awareness of aspergillosis, expansion of hospital treatment capabilities.

The aspergillosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing research into resistant fungal strains, rising demand for personalized treatment approaches, expansion of antifungal drug pipelines, growing adoption of early diagnostic testing, increasing healthcare expenditure on infectious diseases. Major trends in the forecast period include increasing development of novel antifungal therapies, rising adoption of precision diagnostics for early detection, growing focus on targeted treatment protocols, expansion of combination antifungal therapies, enhanced monitoring of treatment outcomes.

The increasing level of healthcare spending is anticipated to drive the growth of the aspergillosis treatment market in the coming years. Healthcare expenditure includes all expenses related to the delivery of health services, family planning initiatives, nutrition programs, and emergency health assistance. An increase in healthcare spending supports the advancement of more effective therapies and medical technologies for treating aspergillosis. For example, in May 2023, the Office for National Statistics, a UK-based government authority, reported that healthcare expenditure in the UK reached approximately $362.08 billion (£292 billion) in 2023, representing a nominal growth of 5.6%. Consequently, rising healthcare expenditures are contributing to the expansion of the aspergillosis treatment market.

Leading companies in the aspergillosis treatment market are concentrating on the development and launch of innovative drugs and treatment solutions to maintain their market presence. The introduction of new medications broadens treatment options for aspergillosis, including posaconazole oral suspension, which offers more precise and effective therapeutic outcomes for patients. For instance, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical firm, introduced posaconazole oral suspension in the US for the treatment of aspergillosis. This medication is intended for patients at high risk of invasive Aspergillus and Candida infections, particularly those with severely weakened immune systems, such as hematopoietic stem cell transplant recipients with graft-versus-host disease. Posaconazole oral suspension is also recommended for treating oropharyngeal candidiasis, especially cases that are refractory to itraconazole and fluconazole.

In October 2023, Basilea Pharmaceutica Ltd, a Switzerland-based biopharmaceutical company, acquired certain assets from Gravitas Therapeutics Inc. for an upfront payment of $2 million, along with potential milestone and royalty payments. Through this acquisition, Basilea seeks to enhance its aspergillosis treatment pipeline by incorporating Gravitas’s clinical-stage antifungal candidate GR 2397, renamed BAL2062, which targets invasive mold infections caused by Aspergillus species. Gravitas Therapeutics Inc., a US-based biotechnology company, developed GR 2397, a novel antifungal agent that demonstrates fungicidal activity against Aspergillus species, including strains resistant to azole therapies.

Major companies operating in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Ltd., Hikma Pharmaceuticals PLC.

North America was the largest region in the aspergillosis treatment market in 2025. The regions covered in the aspergillosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aspergillosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the aspergillosis treatment market by increasing costs of imported active pharmaceutical ingredients, diagnostic reagents, laboratory equipment, and specialized drug manufacturing inputs. Pharmaceutical production and hospital procurement in North America and Europe are most affected due to dependence on cross-border supply chains, while Asia-Pacific faces pricing pressure on API exports. These tariffs are increasing treatment costs and impacting drug availability timelines. At the same time, they are encouraging local API manufacturing, regional drug formulation facilities, and investments in domestic antifungal drug development.

The aspergillosis treatment market research report is one of a series of new reports that provides aspergillosis treatment market statistics, including aspergillosis treatment industry global market size, regional shares, competitors with a aspergillosis treatment market share, detailed aspergillosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the aspergillosis treatment industry. This aspergillosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aspergillosis treatment involves managing a fungal infection caused by the Aspergillus species, with the approach depending on the severity and type of the disease. Aspergillosis can be serious and potentially life-threatening, particularly in individuals with compromised immune systems.

The primary types of aspergillosis treatment include allergic aspergillosis, chronic aspergillosis, invasive aspergillosis, and others. Allergic aspergillosis, also referred to as allergic bronchopulmonary aspergillosis (ABPA), is a distinct type of allergic reaction to the Aspergillus fungus, most frequently caused by Aspergillus fumigatus. The treatment involves various drug classes such as corticosteroids, antifungal drugs, and others. Administration can be through multiple routes including oral, injectable, and others, and the drugs are distributed via several channels such as hospital pharmacies, retail pharmacies, and others.

The aspergillosis treatment market consists of sales of immunotherapy drugs, echinocandin and azole antifungals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.